http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S56127338-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18a7d1606da2ec2ad08ae63822efb00e
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-26
filingDate 1980-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efdeb09ab931fd71e4108f94fce8457b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b06d1f8a2e6d3aea4d289e447ee4d3a
publicationDate 1981-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S56127338-A
titleOfInvention Basic amino acid salt of diclofenac and suppository containing the same
abstract NEW MATERIAL:Basic amino acid salt of 2-(2,6-dichloroanilino)phenylacetic acid (general name: Diclofenac). n EXAMPLE: Diclofenac 1-lysine salt. n USE: Antiphlogistic, analgesic and antipyretic agent for rectal administration. It can be absorbed rapidly through rectum, gives high concentration in blood, and also gives extremely low stimulation to mucous membranes. The distinctive character of this compound is that the side effects such as gastroenteric disorder of the Diclofenac Na salt for oral administation are improved by converting to a suppository preparation. n PROCESS: The reaction of Diclofenac with a basis amino acid, e.g. lysine, arginine, histidine etc., in water-containing methanol gives a salt of formula I (Y is a group of formula II and n is 4 when lysine is used; Y is a group of formula III and n is 3 when arginine is used; Y is a group of formula IV and n is 1 when histidine is used). n COPYRIGHT: (C)1981,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S56138115-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0242809-B2
priorityDate 1980-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S54109942-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3033
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395485
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395154
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395486

Total number of triples: 32.